A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
Phase 3
450
about 2.1 years
18–74
35 sites in AL, AR, CA +15
What this study is about
Researchers are testing a treatment called azetukalner versus a placebo for people with major depressive disorder. The trial will last about 753 days and involve around 450 participants.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Azetukalner
- 2.Take Placebo
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Change from baseline in the Hamilton Depression Rating Scale, 17-item (HAMD-17) score at Week 6
Secondary: Change from baseline in the Clinical Global Impression of Severity (CGI-S) score at Week 6, Change from baseline in the Hamilton Depression Rating Scale, 17-item (HAMD-17) score at Week 1, Change from baseline in the Snaith-Hamilton Pleasure Scale (SHAPS) score at Week 6, To assess the safety and tolerability of azetukalner (e.g., adverse events)
Psychiatry / Mental Health